SIBO: Complete Guide for Brazilian Expats and International Patients

If you have been battling persistent bloating, gas, abdominal pain, brain fog, or unpredictable bowel habits — and no one has been able to explain why — Small Intestinal Bacterial Overgrowth (SIBO) may be the missing piece. As a Brazilian nutritionist who works with patients across multiple countries, I have seen SIBO hide behind “IBS”, “stress”, and “just a sensitive stomach” for years before being identified. This comprehensive guide explains what SIBO is, how it is diagnosed, the hydrogen/methane/hydrogen-sulfide subtypes, and what a specialized nutrition protocol actually looks like.

By Taissa Castello, registered nutritionist CRN-4 25106120, specialized in gut health, SIBO, celiac disease, and food allergies. English teleconsultations available worldwide.

What is SIBO?

Small Intestinal Bacterial Overgrowth (SIBO) is a condition in which an excessive number of bacteria — often of colonic origin — colonize the small intestine. Normally, the small intestine hosts far fewer bacteria than the colon, because this is where most nutrient absorption takes place. When bacteria overgrow in the wrong compartment, they ferment carbohydrates before your body can absorb them, producing excess gases (hydrogen, methane, and sometimes hydrogen sulfide) and causing the classic symptoms of bloating, distension, altered bowel habits, and abdominal pain (Pimentel et al., 2020).

SIBO is not a “fashionable” diagnosis. It is recognized by the American College of Gastroenterology (ACG) 2020 Clinical Guideline and the North American Consensus as a distinct clinical entity with validated breath-test criteria (Rezaie et al., 2017; Pimentel et al., 2020). Prevalence estimates vary widely depending on the population studied, but SIBO is disproportionately common in patients with IBS, post-infectious gastroenteritis, hypothyroidism, diabetes, scleroderma, previous abdominal surgery, and chronic proton pump inhibitor use.

“SIBO is often the root cause behind years of unexplained digestive symptoms. Once we address the bacterial overgrowth and restore the gut’s natural defenses, patients often experience relief they did not think was possible.”

— Taissa Castello, PodIgest

Symptoms — digestive and beyond

SIBO rarely presents as a single symptom. Most patients describe a cluster of complaints that fluctuate over time and often worsen after meals rich in fermentable carbohydrates. The most consistent findings in the literature are:

• Bloating and abdominal distension — often dramatically worse in the afternoon and evening
• Excess gas — belching, flatulence, gurgling sounds
• Altered bowel habits — diarrhea, constipation, or alternating patterns
• Abdominal pain or cramping
• Post-meal fatigue or brain fog
• Nutrient deficiencies — particularly iron, vitamin B12, and fat-soluble vitamins (A, D, E, K)
• Unintentional weight changes — weight loss in classic presentations, weight retention in methane-dominant SIBO
• Skin issues — rosacea is strongly associated with SIBO in the literature

If this list sounds like your daily reality, you are not “complaining too much” and you are not alone. A proper evaluation is the first step.

The three SIBO subtypes: hydrogen, methane, and hydrogen sulfide

SIBO is not a single disease. The gases produced by the overgrown microbes shape the clinical picture, influence which antimicrobial protocol works, and predict relapse patterns.

Hydrogen-dominant SIBO

Hydrogen is produced by bacterial fermentation of carbohydrates in the small intestine. Hydrogen-dominant SIBO typically presents with diarrhea-predominant symptoms, frequent urgency, and postprandial bloating. It generally responds well to rifaximin-based protocols combined with a targeted low-fermentation diet (Pimentel et al., 2020).

Intestinal Methanogen Overgrowth (IMO)

Formerly called “methane-dominant SIBO”, the North American Consensus now uses the term Intestinal Methanogen Overgrowth (IMO) because the responsible organism — Methanobrevibacter smithii — is an archaeon, not a bacterium, and it can overgrow in both the small and large intestine (Pimentel et al., 2020). IMO is the methane-producing form and is strongly associated with constipation, slower gut motility, and difficulty losing weight. Treatment typically requires a dual antimicrobial approach (rifaximin plus neomycin or rifaximin plus allicin) because methane archaea are less sensitive to rifaximin alone.

Hydrogen sulfide SIBO (H2S)

The newest recognized subtype. Hydrogen sulfide is produced by sulfate-reducing bacteria and is associated with “rotten egg” gas, diarrhea, and visceral hypersensitivity. Detection requires a three-gas breath test (trio-smart or equivalent). Management involves restriction of high-sulfur foods during the acute phase alongside targeted antimicrobials.

For a deeper comparison of hydrogen and methane SIBO — why the breath test matters, how treatment differs, and what weight and bowel patterns tell you — see the detailed article (in Portuguese): SIBO de hidrogênio vs. metano (IMO).

How is SIBO diagnosed?

The gold-standard diagnostic test in clinical practice is the breath test. After an overnight fast and a 24-hour low-fermentation preparation diet, the patient drinks a substrate (usually lactulose or glucose) and breath samples are collected every 15-20 minutes for 2-3 hours. Elevated hydrogen, methane, or hydrogen sulfide above validated thresholds confirms overgrowth (Rezaie et al., 2017).

• Lactulose breath test: travels the full length of the small intestine — better at detecting distal SIBO, slightly higher false positives
• Glucose breath test: absorbed in the proximal small intestine — higher specificity, lower sensitivity for distal overgrowth
• Trio-smart (three-gas): measures H2, CH4, and H2S — required to detect hydrogen sulfide SIBO

A small-bowel aspirate and culture remain the theoretical gold standard but are invasive and rarely used outside research settings. In my practice, a well-prepared breath test plus a thorough clinical history is what we use to guide treatment decisions.

Root causes: why SIBO happens

SIBO is almost never the primary disease — it is a consequence of something else disrupting the gut’s natural defenses. Identifying and addressing the underlying cause is what separates a one-time recovery from a lifetime of relapses.

• Impaired migrating motor complex (MMC) — the “housekeeper wave” that sweeps bacteria out of the small intestine between meals. Often damaged after food poisoning (post-infectious IBS)
• Low stomach acid — from chronic PPI use, H. pylori, or age-related hypochlorhydria
• Anatomical changes — adhesions from previous abdominal surgery, diverticula, strictures
• Hypothyroidism — slows gut motility; strongly associated with methane-dominant SIBO
• Diabetes and scleroderma — autonomic neuropathy affecting gut motility
• Chronic constipation — itself both cause and consequence
• Ileocecal valve dysfunction — allowing colonic bacteria to reflux into the small intestine

“When a patient relapses again and again, the question is never ‘why did the SIBO come back?’ — it is ‘what in your system is still allowing the bacteria to overgrow?’ That is where the real work happens.”

— Taissa Castello, PodIgest

Treatment: antimicrobial, nutrition, and motility

Effective SIBO treatment is a three-legged stool: kill the overgrowth, feed yourself without feeding the overgrowth, and restore motility so it does not come back. Skipping any leg predicts relapse.

1. Antimicrobial phase

Pharmaceutical options (prescribed by a gastroenterologist) include rifaximin for hydrogen-dominant SIBO and rifaximin + neomycin for methane-dominant IMO (Pimentel et al., 2020). Herbal antimicrobials — oregano oil, berberine, neem, and allicin — have shown comparable efficacy in a randomized trial and are useful when pharmaceuticals are unavailable or not tolerated (Chedid et al., 2014).

2. Nutritional phase

Dietary strategies reduce the fermentable substrate available to bacteria, easing symptoms during and shortly after antimicrobial treatment. The most commonly used in clinical practice are the low-FODMAP diet, the SIBO Specific Food Guide (SSFG), and the SIBO Bi-Phasic Diet. None should be permanent — prolonged restriction starves beneficial bacteria and can worsen long-term gut health (Staudacher et al., 2017).

3. Motility and prevention

This is the phase most protocols skip — and it is why people relapse. Prokinetic agents (prescription or natural), adequate spacing between meals (4-5 hours to allow the MMC to fire), stress reduction, and treating underlying causes (thyroid, stomach acid, adhesions) are what keep SIBO from returning. For a detailed walkthrough of post-treatment recovery, see (in Portuguese): SIBO pós-tratamento.

SIBO and IBS — the same thing?

No — but they overlap significantly. Studies using breath testing suggest that up to 60-80% of patients with IBS meet criteria for SIBO (Ghoshal et al., 2017). That does not mean every IBS patient has SIBO, but it does mean that a diagnosis of “IBS” without further investigation leaves a large share of patients without an actionable treatment plan. If you have been told you have IBS and standard management is not working, asking about a breath test is reasonable.

SIBO and thyroid disease

Hypothyroidism — particularly Hashimoto’s thyroiditis — is strongly associated with methane-dominant SIBO. The slowed gut motility from low thyroid hormone creates the perfect environment for archaea to overgrow, and many patients present with constipation that is resistant to standard laxative approaches. Treating SIBO in these patients often improves thyroid medication absorption and symptom burden simultaneously. See the companion article on Hashimoto’s thyroiditis and gluten.

Frequently asked questions

Can SIBO be cured or only managed?

SIBO can be fully cleared, but the underlying cause determines long-term outcomes. Patients with a transient trigger (a single food poisoning episode, a short PPI course) often achieve durable remission. Patients with structural causes (adhesions, scleroderma) or chronic motility disease may need ongoing prokinetic support.

Is the low-FODMAP diet a cure for SIBO?

No. The low-FODMAP diet reduces symptoms but does not eliminate the overgrowth. It is a symptom-management tool used during and shortly after antimicrobial treatment — not a permanent diet.

How long does SIBO treatment take?

A typical protocol runs 2-4 weeks of antimicrobials followed by a 4-8 week nutrition and motility phase. Patients with high breath gas values or structural causes may need repeated courses. Expect 3-6 months for full recovery with a well-designed protocol.

Can I treat SIBO while traveling or living abroad?

Yes. Breath tests are available in most major cities worldwide, and teleconsultations allow nutritional and protocol guidance regardless of your location. In my practice I work with patients across Brazil, Europe, North America, and the Middle East using video consultations.

Key takeaways

• SIBO is a real, measurable condition — not a label for unexplained bloating
• Three subtypes (hydrogen, methane/IMO, hydrogen sulfide) require different strategies
• Diagnosis via validated breath testing (Rezaie et al., 2017)
• Treatment is a three-legged stool: antimicrobial + nutrition + motility
• Underlying root causes must be addressed to prevent relapse
• Specialized nutritional support significantly improves outcomes

Ready to take the next step?

If you are looking for specialized nutritional guidance, Taissa Castello offers teleconsultations via Google Meet for patients worldwide. Whether you live in Brazil or abroad, you can get expert, personalized support for your gut health, autoimmune condition, or food allergies — in English or Portuguese.

Or visit the booking page for more options.

References

• Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178.
• Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-784.
• Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24.
• Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11(2):196-208.
• Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527.
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031-2035.

Medical Disclaimer: This article is for informational and educational purposes only. It does not replace individualized medical or nutritional advice, diagnosis, or treatment. Each person has unique needs that must be evaluated in a consultation. Do not start, change, or stop any treatment without guidance from a qualified healthcare professional. Taissa Castello is a registered nutritionist (CRN-4 25106120) and does not prescribe medications. Read our full disclaimer.

Read also: SIBO Symptoms: How to Recognise Bacterial Overgrowth | FODMAP Diet: Complete Guide for IBS and SIBO

SIBO Treatment Protocols: What’s New in 2025–2026

The SIBO treatment landscape has continued to evolve. Here is a summary of the most relevant updates for 2025–2026 based on the latest clinical guidelines and emerging research:

Rifaximin remains the first-line antibiotic for hydrogen-SIBO

Rifaximin (550 mg three times daily for 14 days) remains the preferred antibiotic for hydrogen-dominant SIBO based on the ACG 2020 guideline. Its non-systemic action (it stays in the gut, does not enter systemic circulation) and minimal impact on gut microbiome diversity outside the small intestine make it the treatment of choice. Recent real-world data continue to support its efficacy, with symptom response rates of 40–65% after a single course.

Methane-dominant SIBO (IMO): combination therapy is now standard

For Intestinal Methanogen Overgrowth (IMO) — previously called methane-SIBO — the updated 2025 North American Consensus confirms that rifaximin alone is insufficient. The combination of rifaximin + neomycin (or rifaximin + metronidazole) produces significantly better methane reduction compared to either agent alone. Lovastatin acetate (originally tested as an anti-methanogen agent) showed promise in trials but is not yet widely available as a therapeutic option.

Herbal antimicrobial protocols — growing evidence

A landmark 2014 study by Chedid et al. demonstrated that herbal antimicrobial protocols (containing combinations of herbs such as oregano oil, berberine, allicin, and neem) showed comparable efficacy to rifaximin for hydrogen-SIBO. The 2025–2026 update to this evidence base includes:

• Biofilm disruptors: increasing evidence supports the addition of biofilm-disrupting agents (NAC, EDTA-based products) to antibiotic or herbal protocols, particularly in treatment-resistant cases.
• Phased herbal protocols: sequential use of different herbal antimicrobials over 4–6 weeks, rather than fixed combinations, is being explored for better microbiome preservation.
• Elemental diet: a 2–3 week elemental (pre-digested) diet remains a validated alternative with ~80% response rate in studies, though adherence is challenging due to palatability and cost.

Post-treatment: the relapse problem and what helps

SIBO has a high relapse rate — estimated at 40–70% within 9–12 months without addressing underlying causes. The 2025–2026 focus in SIBO management has shifted significantly toward relapse prevention:

• Prokinetics: agents that stimulate the migrating motor complex (MMC) — the gut’s “cleaning wave” between meals — are now routinely recommended post-treatment. Low-dose erythromycin, prucalopride, and herbal prokinetics (ginger, artichoke extract) are the most studied.
• Low-fermentation diet: a 4–6 week low-FODMAP or specific carbohydrate diet post-treatment reduces substrate for bacterial regrowth while the gut heals.
• Root cause identification: structural issues (adhesions, ileocecal valve dysfunction), motility disorders (hypothyroidism, diabetes), and low stomach acid must be addressed to prevent recurrence.

If you are navigating SIBO treatment options or managing post-treatment recovery, individualized nutritional guidance can significantly improve outcomes. Book a teleconsultation with Taissa Castello, registered nutritionist (CRN-4 25106120), specialized in SIBO and gut health.

Looking for expert SIBO nutritional guidance? Taissa Castello is a specialist nutritionist in gut health and celiac disease, offering teleconsultations worldwide in English and Portuguese. Book via WhatsApp.

Taissa Castello Fonseca

Nutricionista Clínica • CRN-4 25106120

Especializada em doença celíaca, SIBO, doenças autoimunes e saúde da mulher. Celíaca há 9 anos. Atende 100% online para todo o Brasil.

Sobre a Taissa Agendar consulta @taissacastello.nutri